NCT05500079

Brief Summary

The aim of this study is to examine the effect of transcutaneous pulsed radiofrequency current in the treatment of carpal tunnel syndrome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2021

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

August 11, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 12, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

May 16, 2023

Status Verified

May 1, 2023

Enrollment Period

1.8 years

First QC Date

August 11, 2022

Last Update Submit

May 15, 2023

Conditions

Keywords

carpal tunnel syndromepulsed radiofrequency treatmenttranscutaneous pulsed radiofrequency

Outcome Measures

Primary Outcomes (2)

  • Change From Baseline in Pain on the Visual Analog Scale (VAS) at Week 2 and 4

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "0=no pain" and "10=worst pain.

    Baseline, Week 2 and 4

  • Boston Carpal Tunnel Syndrome Questionnaire before treatment

    The Boston Carpal Tunnel Questionnaire (BCTQ) is a disease-specific measure of self-reported symptom severity and functional status. It is frequently used in the reporting of outcomes from trials into interventions for carpal tunnel syndrome. ıncluding Symptom Severity Scale is 11: no symptoms, 55: worst symptoms and Functional Disability Scale (FDS) no difficulties:8, worst difficulties: 40

    Before treatment

Study Arms (2)

Wrist splint group

ACTIVE COMPARATOR

The group to be treated with a wrist splint

Device: Wrist splint

Transcutaneous pulsed RF group

ACTIVE COMPARATOR

The group to be treated with transcutaneous pulsed RF

Other: Pulsed radiofrequency current

Interventions

A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.

Wrist splint group

Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.

Transcutaneous pulsed RF group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Carpal tunnel syndrome detected by electroneuromyography
  • Positive Tinel sign

You may not qualify if:

  • Thenar muscle atrophy
  • Weakness in the abductor pollicis brevis muscle

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diskapi Yildirim Beyazıt Teaching and Research Hospital

Ankara, Dişkapi, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Peripheral Nervous System DiseasesChronic PainCarpal Tunnel Syndrome

Condition Hierarchy (Ancestors)

Neuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMedian NeuropathyMononeuropathiesNerve Compression SyndromesCumulative Trauma DisordersSprains and StrainsWounds and Injuries

Study Officials

  • mehlika panpallı ateş

    Diskapi TRH

    STUDY CHAIR
  • ömer taylan akkaya

    Diskapi TRH

    STUDY DIRECTOR
  • Hüseyin Alp Alptekin

    Diskapi TRH

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, medical doctor

Study Record Dates

First Submitted

August 11, 2022

First Posted

August 12, 2022

Study Start

August 1, 2021

Primary Completion

May 30, 2023

Study Completion

June 1, 2023

Last Updated

May 16, 2023

Record last verified: 2023-05

Locations